Os Therapies INC 8-K filings

OS Therapies Incorporated announced a securities purchase agreement for up to $10 million in senior secured convertible notes to fund clinical development and working capital.

OS Therapies Incorporated has terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading, effective July 28, 2026, after selling a fraction of the available shares.

OS Therapies Incorporated filed an amendment to its Form 8-K to include a side letter dated June 30, 2026, with Leonite Fund I, LP, clarifying terms related to a private placement transaction.

OS Therapies Incorporated announced the closing of a $5.25 million registered direct offering, raising approximately $4.7 million in net proceeds to fund clinical development and research.

OS Therapies Incorporated filed a prospectus supplement covering the resale of up to 10,529,417 shares of common stock by selling stockholders, supported by a legal opinion affirming their validity.

OS Therapies Incorporated announced a private placement of convertible notes and warrants, raising $2 million to fund clinical development and R&D programs.

OS Therapies Incorporated has extended its inducement offer for existing warrant holders to exercise their warrants at a reduced price until March 2, 2026.

OS Therapies Inc. raised $7.53 million in gross proceeds from existing investors through a warrant exercise inducement offer to fund regulatory efforts and a planned spinoff.

OS Therapies Incorporated stockholders approved all six proposals at the 2025 Annual Meeting, including a significant increase in authorized shares and an expanded incentive compensation plan.

OS Therapies Incorporated released an investor presentation highlighting positive Phase 2b clinical data for OST-HER2 in osteosarcoma and outlined a clear path to accelerated FDA approval, alongside an annual meeting adjournment.

OS Therapies Incorporated filed a prospectus supplement for the resale of up to 4,373,043 common shares by selling stockholders, with a legal opinion confirming their validity.

OS Therapies completed a warrant exercise inducement, raising $3.7 million to accelerate commercial preparations for its lead asset, OST-HER2, and extended its funding into 2027.

OS Therapies Inc. has terminated its $15 million Equity Purchase Agreement, citing sufficient funding from a recent warrant exercise and reduced operational burn.

OS Therapies announced positive Phase 2b clinical trial results for OST-HER2 in osteosarcoma, securing FDA RMAT status and a BLA number, alongside a $4.2 million capital raise.

OS Therapies Incorporated has amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of voting power, effective August 15, 2025.

OS Therapies Incorporated successfully closed a warrant exercise inducement and exchange offer, raising approximately $4.2 million in gross proceeds to extend its cash runway through 2026 and advance key clinical and strategic initiatives.

OS Therapies Incorporated announced the completion of the second closing of its warrant exercise inducement and exchange offer, generating approximately $616,000 in gross proceeds.

OS Therapies Inc. announced a warrant exercise inducement and exchange offer to raise approximately $8 million, extending its cash runway into the second half of 2026, and reiterated its timeline for a key FDA submission for its lead asset, OST-HER2.

OS Therapies announced its Q1 2025 financial results, highlighted by progress in its OST-HER2 osteosarcoma program and expansion of its immunotherapy platform.

OS Therapies completes the acquisition of Ayala Pharmaceuticals' listeria-based cancer immunotherapy assets, expanding its clinical pipeline and solidifying its position as a leader in the field.

OS Therapies Incorporated announces stockholder approval for the issuance of common stock upon conversion of preferred stock and exercise of warrants at a Special Meeting held on April 9, 2025.

OS Therapies Inc. adjourned its Special Meeting of Stockholders on March 31, 2025, due to the absence of a quorum and will reconvene on April 9, 2025.

OS Therapies reports its full-year 2024 financial results, highlighting progress with its OST-HER2 clinical trial and strategic initiatives.

OS Therapies has acquired immuno-oncology programs and related intellectual property from Ayala Pharmaceuticals, adding clinical-stage lung and prostate cancer assets to its pipeline and consolidating ownership of its core technology.

OS Therapies finalizes a private placement, raising approximately $7.1 million before expenses.

OS Therapies finalizes a second closing of its private placement, securing additional funds and amending agreements to facilitate future closings.

OS Therapies has successfully closed a $6 million private placement, providing funding expected to last into 2026 and supporting the clinical development of their lead drug candidate.

OS Therapies has successfully priced a $6 million private placement to fund the clinical and regulatory milestones for its lead therapeutic candidate, OST-HER2.

OS Therapies reports its third quarter 2024 financial results, highlighting the completion of its Phase 2b clinical trial for OST-HER2 and anticipating topline data in December 2024.

OS Therapies has entered into an agreement with Square Gate Capital for a $15 million equity line, providing the company with flexible access to capital over the next 24 months.